- Shares of Idera Pharaceuticals (IDRA) are up 20% before the open on heavy volume in response to the firm's report of positive phase 2 clinical trial results for it psoriasis drug IMO-8400.
- The 32-patient study met its primary endpoint of safety and tolerability over a 12-week period. No adverse events, dose reductions or discontinuations occurred.
- The study also met its secondary endpoint of demonstrating clinical activity as assessed by Psoriasis Area and Severity Index (PASI) scores.
- IMO-8400 has demonstrated activity in other autoimmune diseases such as lupus and arthritis.
From other sites
at 4-traders.com (Mar 23, 2015)
Idera Provides Key Updates on Clinical Development of IMO-8400 for Treatment of Waldenstrom's Macroglobulinemiaat Benzinga.com (Dec 30, 2014)
at Nasdaq.com (Dec 16, 2014)
at CNBC.com (Mar 28, 2014)
at MarketWatch.com (Dec 31, 2013)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs